Presentation Slides - February 27, 2014
Stop TB Meeting
Global epidemiology of MDR-TB
Dr. Matteo Zignol, World Health Organization, Geneva, Switzerland
Global laboratory initiative
Dr. Thomas Shinnick, Centers for Disease Control and Prevention, Atlanta, GA, USA
The global drug facility - Not available for download
Dr. Joel Keravec, World Health Organization, Geneva, Switzerland
What will it take?
Dr. Randall Reves, University of Colarado, Denver, CO, USA
Measuring the impact of community engagement on TB clinical trials
Mr. Mike Frick, Treatment Action Group, New York, NY, USA
Active TB case finding post-earthquake in a slum community in Port-au-Prince, Haiti
Mr. Jack Masur, Les Centres GHESKIO, Port-au-Prince, Haiti
Nursing-Sponsored Session
Managing complex cases
Mr. Dennis Francis, McGill University Health Centre, Montreal, QC, Canada
Managing cases through building relationships
Dr. Lisa Gurland, Lemuel Shattuck Hospital, Massachusetts Department of Public Health, Boston, MA, USA
Managing cases across boarders: US, Mexico and Central America
Dr. Carlos Vera-Garcia, Cure TB, Binational TB Program, San Diego, CA, USA
Story telling and First Nations narratives: Facilitating teaching and learning opportunities about TB in BC
Ms. Shawna Buchholz, British Columbia Centre for Disease Control, Vancouver, BC, Canada
Promoting efficacy of TB prevention and treatment in Native American communities
Ms. Denise Genaro Wolf, Public Health Seattle King County, Seattle, WA, USA
Educational resources and apporaches for managing complex TB cases
Ms. Nisha Ahamed, NJMS Global TB Institute, Newark, NJ, USA
Beyond TB Lecture:Community-based care of chronic infectious disease
Dr. Paul Farmer, Harvard Medical School / Partners in Health, Boston, MA, USA
The George Comstock Lecture: Contemporary TB control: The perfect mix of science, technology, marketing, and management capacity
(for presentation slides, please email ferguson-king@bclung.ca)
Dr. Catharina van Wezeenbeek, KNCV, The Hague, Netherlands
Presentation Slides - February 28, 2014
Mutli-Drug Resistant TB
Epidemiology of MDR-TB in North America / Caribbean Regions
Dr. Patrick Moonan, Centres for Disease Control and Prevention, Atlanta, GA, USA
TB drug pipeline and new treatment combinations for MDR-TB
Dr. Robert Horburgh Jr., Boston University School of Public Health, Boston, MA, USA
Management of LTBI caused by MDR-XDR isolates: The cons of susceptibility driven treatment
Dr. Sundari Mase, Centers for Disease Control and Prevention, Atlanta, GA, USA &
Dr. David Ashkin, Florida Department of Public Health, Lantana, FL, USA
Approach to fast track laboratory diagnosis for persons at risk of drug resistant TB:
Molecular detection of drug resistance (MDDR) service
Dr. Beverly Metchock, Centers for Disease Control and Prevention, Atlanta, GA, USA
Advanced diagnostic laboratories
Dr. Max Salfinger, National Jewish Medical and Research Center, Denver, CO, USA
Drug resistant profiles among patients enrolled in a cohort study of TB in Lima, Peru
Mr. Roger Ivan Calderon Espinoza, Socios en Salud Sucursal, Lima, Peru
Against all odds: Early success treating MDR-TB in the US Pacific
Dr. Richard Brostrom, Centers for Disease Control and Prevention, Honolulu, HI, USA
The Difficulty to Treat Patient
Co-mordities in TB diagnosis - Risk factors for activation
(for presentation slides, please email ferguson-king@bclung.ca)
Dr. Marie Turner, Lemuel Shattuck Hospital, Jamaica Plain, MA, USA
TB and the complications of substance abusing clients
Dr. Katina Forrest-Perkins, Prevent Child Abuse Minnesota, Saint Paul, MN, USA
Solving the silent crisis: Advocacy strategies to resolve and prevent domestic drug shortages
Mr. Kanyon Faroow, Treatment Action Group, New York, NY, USA
The hard to treat paediatric/adolescent patient - Not available for download
Dr. Ian Kitai and Mr. Ray Lam, Hospital for Sick Children / University of Toronto, Toronto, ON, Canada
TB exposure, infection, and disease among children with medical co-mordidities
Dr. Andrea Cruz, Baylor College of Medicine, Houston, TX, USA
Diabetes knowledge and self-management among TB patients in Hawaii, 2013
Dr. Bonnie Young, State of Hawaii Department of Health, TB Control Branch, Honolulu, HI, USA
Presentation Slides - March 1, 2014
From the Laboratory to your Clinical Practice
Targeting the organism: Present and future
Dr. Anna Upton, TB Alliance, New York, NY, USA
The host: Immunology and implications for vaccines
Dr. Tom Evans, AERAS, Rockerwille, MD, USA
Genotyping for the diagnosis of drug resistant TB
Dr, Megan Murray, Harvard School of Public Health, Boston, MA, USA
Rapid point-of-care breath test for TB
Dr. Michael Phillips, Menssana Research inc, Fort Lee, NJ, USA
Novel katG mutations identified in Myobacterium TB provide a mroe comprehensive diagnostics for Isoniazid Resistance and better clinical management of drug resistant TB
Dr. Fararmarz Valafar, San Diego State University, San Diego, CA, USA
IGRA testing using a portable incubator
Dr. Maureen Mayhew, BC Centre for Disease Control, Vancouver, BC, Canada
Latency
Evolving science of latency: Potential implications on the diagnosis and treatment of LTBI - Not available for download
Dr. JoAnne Flynn, University of Pittsburgh School of Medicince, Pittsburgh, PA, USA
Programmatic experience with IGRA testing
Dr. Julia Higashi, Curry International TB Center, San Francisco, CA, USA
Programmatic experience with the 12 dose Rifapentine/Isoniazid regimen in the US
Dr. Christine Ho, Centers for Disease Control and Prevention, Atlanta, GA, USA
Impact of screening and treatment of LTBI on TB control and incidence
Screening and treatment as population-based control strategies
Dr. Tim Sterling, Vanderbilt University, Nashville, TN, USA
The limits of screening and treatment for latent TB as a TB control strategy
Dr. Kevin Schwartzman, McGill University, Montreal, QC, Canada
Outcomes of latent TB and screening and therapy in transplant candidates and recipients over a 10 year period
Dr. Aman Sidhu, University of Alberta, Edmonton, AB, Canada
Factors associated with non-completion of latent TB infection treatment: Experiences from the Prevent TB Study
Dr. Ruth Moro, Centers for Disease Control and Prevention, Atlanata, GA, USA